Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Valneva SE ADR (VALN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VALN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.57
1 Year Target Price $13.57
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.05% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 933.35M USD | Price to earnings Ratio - | 1Y Target Price 13.57 |
Price to earnings Ratio - | 1Y Target Price 13.57 | ||
Volume (30-day avg) 4 | Beta 1 | 52 Weeks Range 3.62 - 11.53 | Updated Date 08/15/2025 |
52 Weeks Range 3.62 - 11.53 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.3865 | Actual -0.1632 |
Profitability
Profit Margin -34.15% | Operating Margin (TTM) -22.01% |
Management Effectiveness
Return on Assets (TTM) -6.58% | Return on Equity (TTM) -38.02% |
Valuation
Trailing PE - | Forward PE 666.67 | Enterprise Value 920499198 | Price to Sales(TTM) 4.75 |
Enterprise Value 920499198 | Price to Sales(TTM) 4.75 | ||
Enterprise Value to Revenue 4 | Enterprise Value to EBITDA 26.94 | Shares Outstanding 85031904 | Shares Floating 126376941 |
Shares Outstanding 85031904 | Shares Floating 126376941 | ||
Percent Insiders - | Percent Institutions 0.82 |
Upturn AI SWOT
Valneva SE ADR
Company Overview
History and Background
Valneva SE ADR (VALN) is an Austrian-French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet medical needs. Founded in 1999, Valneva has grown through strategic acquisitions and internal development, establishing a diverse portfolio of vaccines.
Core Business Areas
- Travel Vaccines: Includes vaccines like IXIARO/JESPECT (Japanese encephalitis vaccine) and DUKORAL (cholera vaccine), primarily aimed at travelers.
- Lyme Disease Vaccine: Valneva is developing VLA1553, a Lyme disease vaccine candidate in Phase 3 clinical trials.
- Other Vaccines: Includes vaccine development programs for chikungunya and other infectious diseases.
Leadership and Structure
Valneva SE is led by Thomas Lingelbach (CEO) and Franck Grimaud (CSO). The company operates with a functional organizational structure, dividing its operations into research & development, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- IXIARO/JESPECT: Japanese encephalitis vaccine. Competitors include Sanofi (JE-Vax). Market share varies by region, but Valneva is a significant player in the market. Revenue not publicly disclosed per product.
- DUKORAL: Cholera vaccine. Competitors are limited, placing Valneva as a market leader in regions where the vaccine is approved. Revenue not publicly disclosed per product.
- VLA1553: Lyme disease vaccine candidate (Phase 3). There are no currently approved human Lyme disease vaccines; Pfizer is a partner. This would be a novel offering in a large, underserved market.
Market Dynamics
Industry Overview
The vaccine market is growing due to increasing awareness of preventative healthcare, rising incidence of infectious diseases, and technological advancements in vaccine development. The market is highly regulated and competitive.
Positioning
Valneva is positioned as a specialty vaccine company focused on niche markets with significant unmet medical needs. Their competitive advantage lies in their specialized expertise and proprietary vaccine platforms.
Total Addressable Market (TAM)
The total vaccine market is expected to be over $100 Billion by 2030. Valneva is positioned to capture a small percentage of this market through their key offering and innovative pipelines.
Upturn SWOT Analysis
Strengths
- Specialized expertise in vaccine development
- Established commercial infrastructure for travel vaccines
- Promising Lyme disease vaccine candidate (VLA1553)
- Partnerships with major pharmaceutical companies
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a few key products
- High regulatory hurdles for vaccine approval
- Dependency on successful Lyme disease vaccine development
Opportunities
- Expanding into new geographic markets
- Developing vaccines for emerging infectious diseases
- Leveraging partnerships for commercialization
- Acquiring complementary vaccine technologies
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Adverse events associated with vaccines
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- SNY
Competitive Landscape
Valneva competes with larger pharmaceutical companies with greater resources. Valneva's competitive advantage lies in its specialization in niche markets and its innovative vaccine technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on commercial success of existing vaccines and progress of vaccine candidates in clinical development.
Future Projections: Future growth is largely dependent on the successful development and commercialization of VLA1553 (Lyme disease vaccine), and the development of other new vaccines.
Recent Initiatives: Recent initiatives include advancing VLA1553 into Phase 3 clinical trials and expanding commercial operations in key markets.
Summary
Valneva is a specialty vaccine company with established travel vaccines and a promising Lyme disease vaccine candidate. The company's growth is dependent on the success of its pipeline, particularly VLA1553. Valneva faces competition from larger pharmaceutical companies and regulatory hurdles. Financial performance is unavailable for the ADR, which prevents detailed analysis. The company's future prospects are tied to pipeline achievements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Valneva SE Investor Relations
- Company Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Valneva SE ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-05 | President, CEO & Director Mr. Thomas Lingelbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 700 | Website https://valneva.com |
Full time employees 700 | Website https://valneva.com | ||
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.